0
₹0 0
Nextgen Biotech

Call us:

menu

Doceaqualip (20mg / 80mg) - Docetaxel Lipid Suspension For Injuction

Doceaqualip (20mg / 80mg) - Docetaxel Lipid Suspension For Injuction

Doceaqualip is a lipid-based formulation of Docetaxel, a chemotherapy drug used to treat various cancers including breast, lung, prostate, and gastric cancers. The lipid suspension improves tolerability and reduces side effects compared to conventional docetaxel.

Select the packing Size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Docetaxel
Brand Name: Doceaqualip
Packing: Single-use vial
Strength: 20 mg/0.5 mL and 80 mg/2 mL
Manufacturer: Intas Pharmaceuticals Ltd
Form: Injectable lipid suspension
Category: Antineoplastic agent (Taxane class), Chemotherapy drug
Product Intro:
Doceaqualip is a novel, solvent-free formulation of Docetaxel that uses lipid-based delivery to reduce hypersensitivity reactions and improve patient safety. It is administered via intravenous infusion and is widely used in oncology for its potent anticancer activity.
Uses (Indications):
  1. Breast Cancer – locally advanced or metastatic
  2. Non-Small Cell Lung Cancer (NSCLC) – alone or in combination
  3. Prostate Cancer – metastatic, hormone-refractory
  4. Gastric (Stomach) Cancer – advanced or metastatic
  5. Head and Neck Cancer – in combination chemotherapy regimens
  6. Ovarian Cancer – in some cases, as part of combination therapy
Storage Instructions:
  1. Store under refrigeration at 2°C to 8°C (do not freeze)
  2. Keep the vial in outer carton to protect from light
  3. Do not use if solution appears cloudy or contains particles
  4. Once diluted, use immediately or store under controlled conditions as per label instructions
How It Works (Mechanism of Action):
Docetaxel promotes the assembly of microtubules and inhibits their disassembly, disrupting cell division. This stabilizes microtubules and leads to apoptosis (programmed cell death) in cancer cells. The lipid-based formulation enhances drug delivery and reduces toxicity compared to solvent-based versions.
Side Effects:
Common Side Effects:
  1. Hair loss (alopecia)
  2. Nausea and vomiting
  3. Diarrhea
  4. Fatigue
  5. Low white blood cell count (neutropenia)
  6. Mouth sores (mucositis)
Serious Side Effects:
  1. Severe neutropenia leading to infection
  2. Hypersensitivity reactions (less common with lipid-based form)
  3. Peripheral neuropathy (numbness or tingling in hands/feet)
  4. Liver toxicity
  5. Fluid retention (edema, pleural effusion)
  6. Cardiovascular complications (rare)
Dosage (Typical Recommended Dose):
  1. Breast Cancer: 75–100 mg/m² IV once every 3 weeks
  2. Lung Cancer: 75 mg/m² IV in combination or as monotherapy
  3. Prostate Cancer: 75 mg/m² IV every 3 weeks with prednisone
  4. Dose adjustments are made based on toxicity, liver function, and patient tolerance
  5. Pre-medication with corticosteroids is often required to prevent fluid retention
Method of Administration:
  1. Given as an intravenous infusion by trained medical professionals
  2. Usually over 1 hour, depending on dose and treatment plan
  3. Pre-medications (e.g., dexamethasone) may be required 1–3 days before infusion
  4. Do not administer as a bolus injection
  5. Monitor for allergic reactions during and after infusion
Precautions:
  1. Requires liver function testing before and during therapy
  2. Neutrophil counts must be monitored – delay treatment if too low
  3. Use with caution in patients with fluid retention or heart disease
  4. Not recommended during pregnancy – causes fetal harm
  5. Avoid breastfeeding during and for weeks after treatment
  6. Patient must be well hydrated before infusion
Drug Interactions:
  1. CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) – may increase toxicity
  2. CYP3A4 inducers (e.g., rifampin, phenytoin) – may reduce effectiveness
  3. Antifungals, antivirals, and some antibiotics – can interact and require monitoring
  4. Avoid concurrent use with other bone marrow suppressants unless advised
Allergies (Warnings for Allergic Reactions):
  1. Hypersensitivity is rare with lipid-based docetaxel but may still occur
  2. Symptoms include rash, itching, facial swelling, shortness of breath
  3. Infusion should be stopped immediately if any severe allergic reaction occurs
Overdose Information:
  1. Overdose symptoms include severe neutropenia, mucositis, and liver damage
  2. There is no specific antidote
  3. Supportive care is required in an intensive care setting
  4. Hematological support (e.g., G-CSF, transfusions) may be necessary
Missed Dose Instructions:
  1. This medicine is administered by a healthcare provider; missed doses are rare
  2. If a dose is missed due to low blood counts or illness, it will be rescheduled by the oncologist
  3. Do not self-administer or attempt to reschedule without consulting your doctor
Additional Notes:
  1. Lipid formulation improves safety by avoiding polysorbate 80 (linked to hypersensitivity in traditional docetaxel)
  2. Strict blood count and liver monitoring are essential before each dose
  3. Notify your doctor if you experience fever, mouth ulcers, breathing difficulty, or unusual bruising
  4. Alcohol consumption should be limited as the liver metabolizes docetaxel
  5. May require supportive medicines like G-CSF to help with low blood counts

In The Same Category

Cart